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Abstract:  Target-focused compound libraries are collections of compounds which are designed to interact with an 
individual protein target or, frequently, a family of related targets (such as kinases, voltage-gated ion channels, 
serine/cysteine proteases). They are used for screening against therapeutic targets in order to find hit compounds that 
might be further developed into drugs. The design of such libraries generally utilizes structural information about the 
target or family of interest. In the absence of such structural information, a chemogenomic model that incorporates 
sequence and mutagenesis data to predict the properties of the binding site can be employed. A third option, usually 
pursued when no structural data are available, utilizes knowledge of the ligands of the target from which focused libraries 
can be developed via scaffold hopping. Consequently, the methods used for the design of target-focused libraries vary 
according to the quantity and quality of structural or ligand data that is available for each target family. This article 
describes examples of each of these design approaches and illustrates them with case studies, which highlight some of the 
issues and successes observed when screening target-focused libraries. 
Keywords: Library design, target focus, kinase, ion channel, GPCR, PPI, HTS, hit rate, BioFocus, Galapagos, SoftFocus. 
INTRODUCTION 
  Identifying novel and robust chemical starting points 
remains one of the biggest challenges in drug discovery 
today. Over the last decade, it has been common practice 
during the early stage of a project to screen vast numbers of 
compounds in high-throughput assays in order to identify 
those chemicals which have the potential to modulate the 
target of interest. The costly nature of such mass screening, 
the consequent need to use reductionist assays that are 
optimized primarily for scale and speed, and the increasing 
realization that drug property space is far from random has 
more recently led to the use of smaller, higher quality 
screening collections. The type of compounds selected for 
these collections is of the utmost importance. 
  Many strategies exist that seek to build such optimal 
initial screening collections. Most organizations now tend to 
prefer highly curated collections which have been selected to 
be drug-like or lead-like and to have high ligand efficiency 
[1]. In particular, experience has shown that eliminating 
compounds with undesirable molecular features (e.g. [2]), be 
they overt (e.g. electrophiles) or more subtle (e.g. 
toxicophores), reduces the incidence of false positives and 
improves the optimization performance downstream, thereby 
conserving valuable resources [3]. 
  Several complementary strategies are employed in 
screening: the use of diverse small molecule libraries, target-
focused libraries, natural products, and fragment collections. 
All of these approaches have their own particular advantages 
and disadvantages. 
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  A target-focused library is a collection of compounds 
which has been either designed or assembled with a protein 
target or protein family in mind. The premise of screening 
such a library is that fewer compounds need to be screened 
in order to obtain hit compounds. Furthermore, it is generally 
the case that higher hit rates are observed when compared 
with the screening of diverse sets, and the hit clusters 
obtained from a successful focused library screening 
campaign usually exhibit discernable structure-activity 
relationships that facilitate follow up of these hits [4]. 
  Focused libraries may be selected from larger, more 
diverse collections using computational techniques such as 
in silico docking to the target or ligand similarity 
calculations using molecular fingerprints. This retrospective 
approach to the selection of compounds has been reviewed 
elsewhere [5]; the focus of this article is the rational, 
prospective design of target-focused libraries. 
  Target-focused libraries are designed based upon some 
understanding of the target or target family of interest. The 
design can be based on target structural data (commonly 
used in the kinase, protease or nuclear receptor fields where 
crystallographic data are abundant), or, where target 
structural data are more scarce but sequence data and 
mutagenesis data are abundant, on broader chemogenomic 
principles (for example, with GPCR and ion channel targets). 
Alternatively, approaches based on the properties of known 
ligands can be deployed; these are applicable to all targets 
and target families provided that high quality ligand data are 
available – such approaches offer a useful way of “scaffold 
hopping” from one ligand class to another [6]. 
  Target-focused libraries are often based around a single 
core or scaffold with one or more (typically 2 or 3) 
attachment points to which are appended specific substi-522   Combinatorial Chemistry & High Throughput Screening, 2011, Vol. 14, No. 6  Harris et al. 
tuents, or side chains, to arrive at the desired molecules. A 
scaffold diversified at two or three attachment points of 
diversity would, if all possible combinations were 
considered, generate a library of many thousands of 
compounds. Generally, a subset of these is chosen for 
synthesis, often around 100-500 compounds, selected to 
fully explore the design hypothesis efficiently and to adhere 
to drug-like properties. 
  When deciding the minimum size of the library several 
factors need to be considered including the tractability of the 
target, maximizing the efficiency of the chemistry and the 
importance of observing initial structure-activity 
relationships (SAR) in the hit clusters. Some guidelines 
related to the SAR issue have been proposed [4]. In 1999, 
the BioFocus group pioneered the design and commercial 
production of novel target-focused libraries and, since its 
SoftFocus
® range of libraries were first made available, they 
have contributed significantly to clients’ drug discovery 
efforts, leading to more than 100 patent filings [7] and nine 
published co-crystal structures, available from the Protein 
Data Bank (PDB) [8]: PDB codes 2R3A, 2R3G [9], 3F2A 
[10], 2C3I [11], 2PMN [12], 3IW8 [13], 3E7V, 3F2N and 
3BQR. They have also contributed directly to the discovery 
of several clinical candidates [14]. This paper illustrates the 
design methods used to target several distinct gene families, 
outlining a variety of different approaches available and 
showing the success of these approaches in several case 
studies. In particular, it highlights how well-designed, target-
focused libraries give higher hit rates than diverse 
collections, often offering potent and selective molecular 
starting-points that can dramatically reduce the subsequent 
hit-to-lead timescale. 
  Given the advantages of target-led approaches, where 
they are possible, over the erstwhile more popular diversity-
led paradigm, it is no surprise that the use of focused 
libraries is increasing. 
METHODS FOR DESIGN 
General 
  For each individual chemotype within a library, the 
design process starts with the selection of a suitable scaffold, 
to which recognition elements (also called substituents or 
side chains) can be appended such that the assembled 
molecule is predicted to interact, in a generic sense, with the 
target family of interest. The assumption is that, for 
individual targets within the family, at least one of the 
possible combinations of scaffold and substituents will 
provide a good fit and therefore give a good screening hit. In 
selecting such scaffolds and substituents, it is crucial that 
careful consideration is given to synthetic accessibility, 
especially that the proposed chemistries are suitable for 
multiple parallel production and purification methods. 
Kinase Library Design 
  Protein kinases are one of the most important families of 
therapeutic targets with broad implications in cancer, 
inflammation and many other diseases. This family has been 
widely explored by a variety of screening techniques. When 
designing a library to inhibit a single kinase the process is 
relatively straightforward. The situation is more complex 
when the library is instead designed against the kinase 
superfamily (kinome), or major sub-families, as each 
individual kinase has its own unique requirements for ligand 
binding. Across the kinome the degree of similarity between 
individual kinases differs so the key binding points for 
ligands may vary, thus potentially impacting the usefulness 
of the library. One can identify a scaffold that can hit 
multiple kinases by docking it into known kinase structures. 
Docking a scaffold into all published kinase structures is 
neither feasible (because the docking and analysis process 
would be too lengthy), nor desirable (because the most 
popular targets are overrepresented). A better strategy is to 
evaluate the scaffold by docking it into a representative 
subset of kinases, where each member is carefully chosen to 
represent a group of targets. To generate this subset, 
BioFocus grouped all public domain crystal structures 
according to protein conformations (e.g., active/inactive, 
DFG in/DFG out) and ligand binding modes. Non-classical 
binding modes were included to ensure that the scaffolds 
evaluated could be used to design innovative libraries with 
novel vectors. From each group one structure was selected, 
for a total of 7 (Table 1). Using multiple binding modes and 
multiple protein conformations is expected to implicitly 
account for the observed plasticity of the kinase binding site 
upon ligand binding. Minimally substituted versions of the 
scaffolds are docked without constraints into this subset of 
kinase structures. Each reasonable docked pose is assessed 
and scaffolds are accepted or rejected based, for example, on 
their predicted ability to bind multiple kinases in either the 
active or various inactive states. Emphasis then shifts 
towards side chains (substituents), selection of which should 
reflect the size and environment of the pockets which are 
targeted. For each panel member, the most appropriate side 
chains are predicted from the bound pose. Combining the 
results for every panel member generates a description of the 
size and nature of the side chains for the family. Under 
certain circumstances conflicting requirements result: for 
example, kinase 1 prefers small hydrophobes in pocket A, 
whereas kinase 2 prefers large, flexible polar groups in the 
same pocket. In this situation, both side chains are 
deliberately sampled within the library and it is this 
underlying softening concept that offers both coverage and 
potential selectivity within a library. 
Table  1.  The Kinases with Associated Classification that 
Make Up the BioFocus Library Evaluation Panel 
 
Kinase  Crystal Structure Used  
(PDB Access Code) 
Classification 
PIM-1 2C3I  Inactive  conformation 
MEK2 1S9I  Active  conformation 
P38 1WBS  Inactive  conformation 
AurA 2C6E  Inactive  conformation 
JNK 2GMX  Active  conformation 
FGFR 2FGI  Active  conformation 
HCK 1QCF  Active  conformation 
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  Whereas the initial design work focused on developing 
scaffolds with a correctly orientated hydrogen bonding 
donor-acceptor pair in order to mimic the binding of ATP 
within the hinge region, recent work has been focused on 
alternative binding modes, especially those associated with 
inactive conformations of the kinase. Three distinct 
approaches to kinase-focused library design are applied at 
BioFocus: hinge binding, DFG-out binding and invariant 
lysine binding. 
Hinge Binding (ATP-Competitive; Type I [15]) 
  The key feature of most scaffolds designed to interact 
with the hinge is a “syn” arrangement of adjacent hydrogen 
bond donor-acceptor groups [16]. The side chains of such 
compounds generally make additional interactions in pockets 
not utilized by ATP and therefore provide both additional 
affinity and a degree of selectivity for the target kinase. For 
example, one set of docking results from a 
pyrazolopyrimidine scaffold is shown in Fig. (1). 
 
 
 
 
 
 
 
 
Fig. (1). Proposed binding mode resulting from a 
pyrazolopyrimidine scaffold docked into Aurora A kinase. The 
hinge region is shown in pink and the activation loop in orange (For 
interpretation of the references to color in this figure legend, the 
reader is referred to the web version of this paper). 
 
  Using the example shown in Fig. (1), when selecting the 
side chains for this library, the predominant characteristics of 
the R
1 group, circled in yellow, would be hydrophilic, since 
R
1 is predicted to point towards the solvent pocket, and those 
of the R
2 group, circled in blue, would be hydrophobic, since 
this is predicted to occupy the lipophilic site. Also included 
within the selection of substituents should be privileged 
groups [17] which are known to be important for binding to 
certain kinases. Finally, within each group of substituents, 
some side chains should be chosen simply to enhance the 
diversity of the final library, thus notionally increasing the 
chance of hitting other diverse kinases not well represented 
in the docking set. 
DFG-Out Binding (Non-ATP-Competitive, Type II [15]) 
  A more recent approach to the design of kinase libraries, 
with arguably higher selectivity potential [15, 18], has been 
to target the so-called DFG-out allosteric pocket adjacent to 
the ATP site. This pocket is formed when the activation loop 
of certain kinases undergoes a major conformational shift 
which disrupts the active conformation. BioFocus has 
developed a generalized binding model of the DFG-out 
pocket which enables the targeting of a range of related 
inactive kinase conformations. The key recognition element 
in DFG-out inhibitors is an “anti” arrangement of adjacent 
hydrogen bond donor-acceptor groups, such as those 
typically seen in an amide, urea or exocyclic aminoaza 
heterocycles. 
Invariant Lysine Binding (Non-ATP-Competitive) 
  This design strategy is largely based on the novel binding 
mode observed in the co-crystal structure of a potent 
SoftFocus Kinase library (SFK33) compound bound to the 
kinase PIM-1 [11], wherein the compound binds to the 
catalytic lysine residue, making no obvious contact with the 
hinge region. SFK33 has proven to be a very prolific source  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Selection of crystallized SFK library compounds in the public domain (a) hinge binding: SFK03 compound bound to CDK2 (PDB 
code 2R3F); (b) DFG-out binding: SFK48 compound bound to p38 [13] (PDB code 3IW8); (c) invariant lysine binding: SFK33 compound 
bound to PIM-1 [11] (PDB code 2C3I). The hinge region is shown as a purple ribbon in each case (For interpretation of the references to 
color in this figure legend, the reader is referred to the web version of this paper). 
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of hits [11, 12] and this novel binding mode, which does not 
depend on the hinge sequence, provides a unique paradigm 
for novel library design. 
  Examples of scaffolds from each of these three design 
approaches together with their observed binding modes are 
shown in Fig. (2). 
  An appropriately designed scaffold can be successfully 
docked by adopting more than one of the binding modes 
listed above. In such cases, the design of the library and 
selection of the final substituents should take account of each 
predicted binding mode and any potential hybrid modes. 
Details on how these libraries compare to diverse collections 
in terms of screening success are reported later in this paper. 
Ion Channel Library Design 
  In contrast to protein kinases, where a vast amount of 
structural data is available, including the structures of 
ligands bound to both active and inactive forms of the 
enzymes, there is very limited structural information for ion 
channel targets. This is due in large part to the difficulty in 
crystallizing membrane bound proteins. Therefore when 
designing ion channel libraries, a strategy that is not wholly 
reliant on available structural data is necessary. 
  Two complementary methods for the design of ion 
channel libraries have been used at BioFocus. The first, 
Helical Domain Recognition Analysis (HDRA), is a 
chemogenomic technique used to target the pore region of 
voltage-gated ion channels (VGICs). The second technique 
is ligand-based and relies on the abundance of historical 
biological data in the ion channel field. It is applied 
primarily to ligand-gated ion channels (LGICs), where the 
binding site is generally not within the conserved pore region 
and therefore where little structural information is available. 
A comparison of the methods used to develop each design 
tool is shown in Fig. (3). 
Voltage-Gated Ion Channels (VGICs) 
  The VGIC family of proteins all exhibit a tetrameric 
assembly of four individual transmembrane helical bundles 
that together comprise an ion-conduction pore and gating 
mechanism. The existence of a common general architecture 
across the VGIC family provides the basis for a general 
design strategy that can be customized to particular VGIC 
sub-types. The judicious use of the published VGIC 
structures, described e.g. in [19],  in conjunction with 
sequence alignment, site-directed mutagenesis data and 
abundant ligand SAR allows a focused library approach 
analogous to that used in the kinase field. 
  The tetrameric helical assembly in calcium and sodium 
channels is covalently linked whereas in potassium channels 
this is not the case. These latter channels can therefore exist 
either as homo or hetero tetramers. Using information from 
published crystal structures and mutagenesis data, it is 
possible to construct a universal sequence alignment for the 
VGIC family which is very useful in exploring VGIC ligand 
recognition across all the diverse VGIC subtypes. Using 
these alignments and published mutagenesis data, the 
specific key amino acid residue positions that are implicated 
in binding small molecules within the pore region can be 
identified. In general, these residue positions are in close 
proximity, forming clusters either on the same or adjacent 
helices. These clusters constitute small pockets, which, by 
analysis of ligand SAR, can be associated with the preferred 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Approaches to ion channel library design. 
Collate literature data
Create sequence alignment Select 3-4 known compounds of similar 
activity against same target(s)
VGIC library design (chemogenomic) LGIC library design (ligand based)
Interpret mutagenesis data for ligand 
interactions
Generate logical map of ligand
Generate proposed bioactive conformation
yg g( )
Generate Field pattern Generate logical map of ligand 
accessible amino acid residues
Characterize fragment recognition sites 
across VGICs
Generate Field pattern
Search database of virtual 
scaffolds/compounds to find suitable matches 
(iterative process)
Develop Scaffold/Ligand Binding 
Hypothesis
Select side chains based on analysis of 
fragment recognition sites
Select side chains based on known SAR within 
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binding of small chemical moieties. By analyzing the amino 
acids present in each of these small pockets, the properties of 
the binding environment can be assessed (Table 2). 
  Using this approach, the whole pore region of VGICs can 
be partitioned into small binding pockets. In Table 2, the 
sequence numbering used is that from the KcSA structure 
but, using the sequence alignment for any ion channel of 
interest, the actual residues present at each highlighted 
position are known and therefore the overall binding 
characteristic of each channel can be classified according to 
the residues present. 
  The result of this approach is a generalized model of the 
pore region of VGICs, which is an approximation between 
the open and closed channel forms. Although relatively little 
is known about the precise movements within the pore 
during ion channel gating, recent crystallographic data 
suggests that movement is greatest at the intracellular ends 
of the helices and that the selectivity filter remains relatively 
unchanged. This is clearly illustrated in Fig. (4) where the 
crystal structures of the closed (pane a), partially-open (pane 
b) and open (pane c) forms of a VGIC are presented. 
  Using this method, the characterization of compound 
binding interactions within the pore can ensure the 
appropriate selection of substituents for library design. 
Furthermore, since this approach is not encumbered by 
considerations of state dependence, the resulting libraries 
have potential to provide both channel blockers and openers. 
Representative examples of scaffolds developed into ion 
channel libraries are shown in Fig. (5). 
Ligand-Gated Ion Channels (LGICs) 
  In contrast to VGICs, the architecture across the ligand 
gated ion channels (LGICs) superfamily is not conserved and 
several sub-types exist, comprising trimeric, tetrameric and 
pentameric sub-units. This makes it difficult to devise a 
generic approach to pore-binding ligands. Furthermore, for 
known ligands, the binding domain within LGICs is located 
outside the pore region, which, being more variable and 
flexible, is very difficult to target using structure-based 
approaches. Therefore LGIC-focused library design using a 
chemogenomic approach such as HDRA is not feasible. 
However, a wealth of SAR information on LGIC ligands 
exists, which can be used as a starting point for library 
Table 2.  An Example Sub-Pocket of Five Different Channels, Showing how the Amino Acids Occupying these Defined Residue 
Positions Determine the Property of the Corresponding Ligand Moiety 
 
Residue Position in Sub-Pocket (Based on KCSA Numbering) 
Channel 
75  99 100 100 103 104 107 
Property of Ligand Moiety Recognized 
Kir1.4 T  T  T T E  I  T  Basic  amine 
hERG  S  G  S  S  Y  A  F  Basic amine/aromatic ring 
Cav1.1 
D2 
D3 
G G  N   
A 
L L F 
H-bonding 
Kv1.1 T  G  V  V I A V  Lipophilic 
Kvlqt1 T  A  V V  F A A  Lipophilic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Model of voltage-dependent gating from KCSA mutant crystal structures, (a) closed channel state (PDB code 2JK5) viewed from 
the side and top respectively, (b) partially open state (PDB code 3F7Y) viewed from the side and top respectively and (c) fully open channel 
state (PDB code 3F5W) viewed from the side and top respectively. 
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design using well-established pharmacophore approaches 
based on ligand structural comparisons. A more recent 
variant of this approach, which is proving to be very 
powerful, is to use a model of the molecular field of a ligand 
rather than its atom connectivity description to generate a 
common-field hypothesis of the bound conformations of a 
series of ligands. Once generated, this field pharmacophore 
can then be used to scan field databases to identify new 
scaffolds and therefore new chemical series. One such 
approach, used by BioFocus, employs the FieldTemplater 
software from Cresset BioMolecular Discovery [20]. 
FieldTemplater generates a model through alignment of 
multiple reference compounds which are conformationally 
sampled then aligned through matching of complementary 
field points. Fig. (6) shows a potent (10-100 nM range) 
TrpV1 ligand [21]
  and the resultant library scaffold for 
FFI01 (FieldFocus Ion channel library FFI01) designed to 
match the key field points. 
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Fig. (5). Example scaffolds. SFI (SoftFocus Ion channel) libraries 
are designed using HDRA to target the pore region of VGICs. FFI 
(FieldFocus Ion channel) libraries are designed to target LGICs 
using a ligand based design approach. 
  It should be noted that by the very nature of the ligand-
based field model, libraries designed using this approach will 
generally be constrained to target a much smaller family of 
proteins, which share closely-related ligand SAR, in contrast 
to the more generic approach that can be used when protein 
structural information is available. With this in mind, 
BioFocus has developed a series of libraries targeting 
transient receptor potential channels (TRPs) – a small sub-
family of ~21 channels. 
GPCR Library Design 
  As with the VGICs, the transmembrane helical regions of 
the G-protein coupled receptors (GPCRs) exhibit spatially-
conserved clusters of amino acids which constitute sub-
pockets whose individual properties determine the binding of 
many of their ligands. This is true for GPCR Family A, for 
which the majority of agonists and antagonists are known 
from abundant mutagenesis data to bind into these 
transmembrane regions, thus allowing the design of focused 
libraries for these families [22]. In the case of GPCR 
Families B and C, this approach is also viable when targeting 
libraries of allosteric modulators which also bind within this 
trans-membrane region. However, such an approach would 
not be suitable to Family B and C orthosteric agonist library 
design since the natural ligand binding site is located on the 
extracellular loops [23].  Together with  the kinase library 
area, the design and screening of GPCR-focused libraries has 
been one of the major efforts of many groups over the last 
decade, including the one at BioFocus.  The library design 
principles and the Thematic Analysis tool developed at 
BioFocus to carry out the design (similar to the HDRA 
program) have been published previously [24]. More details, 
including synthesis and screening results, will be reviewed in 
a forthcoming paper [22]. 
Protein-Protein Interactions Library Design 
  The field of protein-protein interactions (PPIs) is one 
which, until recently, has not been tackled using focused 
libraries, one of the few exceptions being the beta-turn 
peptidomimetic libraries targeting integrin binding reported a 
decade ago [25]. Recently, several reports have demonstrated 
that mimics of other protein paratopes such as alpha helices 
and beta sheets can also be successful in generating small 
molecule protein-protein interaction inhibitors (SMPPIIs) 
[26, 27]. These observations coupled with a rise in reports of 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Field based scaffold library design. Template and resultant scaffold for the TRP family of ligand gated ion channels, showing field 
patterns for a synthetic TRPV1 agonist (a) and the FFI01 scaffold (b). Blue, red and grey spheres represent negative electrostatic, positive 
electrostatic and neutral hydrophobic field points, respectively (For interpretation of the references to color in this figure legend, the reader is 
referred to the web version of this paper). Design and Application of Target-Focused Compound Libraries  Combinatorial Chemistry & High Throughput Screening, 2011, Vol. 14, No. 6    527 
drug-like SMPPIIs for a variety of target proteins, have led 
several groups, including BioFocus, to develop new 
approaches to the design of generic PPI libraries, as opposed 
to those aimed at a single protein target. 
  Of course, PPIs are ubiquitous in biological systems and, 
in order to devise a rational approach to targeting them, 
some level of focus is mandatory. Without further defining 
their physiological function, PPIs can be classified according 
to the types of biochemical processes in which they are 
involved; for example, substrate binding to kinases or 
acetylated histone binding to bromodomains [28]. However, 
a more generic and useful way to classify them is according 
to the secondary structural elements involved, for example 
where the principal interacting element is an alpha helix, a 
beta sheet, or perhaps the residues presented at the periphery 
of a beta-bend. Using such a classification approach, it is 
possible to design small molecules that mimic the key 
features found in these types of interacting elements, most 
notably hydrogen bonding patterns and the properties and 
trajectories of the amino acid side chains involved. These 
features can thus be incorporated into scaffold designs 
exactly as outlined for the kinases and voltage-gated ion 
channels and used to generate small molecule libraries for 
screening against a wide range of protein-protein 
interactions. Thus, PPI libraries are designed to mimic the 
key features found in secondary structural elements involved 
in protein-protein interactions. 
  For many years, the view was that to effectively mimic 
an alpha helical or beta sheet based interaction, one would 
require large, non-drug-like molecules. Indeed many large, 
nominally non-drug-like compounds have been reported as 
helix mimetics and terphenyl structures as mimics of the 
peptide backbone [29]. 
 
 
 
 
 
 
 
 
 
 
Fig. (7). BCL-XL (green) with the peptide BAD (red); typical alpha 
helix structure with side chain vectors shown in red superimposed 
with a biphenyl (in yellow); overlay of a biphenyl with a 
cyclopropylphenyl, HM01 scaffold and an example of HM01 
overlaid onto an alpha helix (For interpretation of the references to 
color in this figure legend, the reader is referred to the web version 
of this paper). 
  The approach adopted at BioFocus for the design of helix 
mimetic libraries is illustrated in Fig. (7) for a specific 
library scaffold (HM01). It has previously been reported that 
the tetra substituted biphenyl scaffold mimics the backbone 
of an alpha helix with the 2-,3-,2’- and 3’- side chains of the 
biphenyl presenting the same trajectories as the helical side 
chains [30]. The biphenyl scaffold itself is inherently 
lipophilic and non-drug-like and, moreover, offers little 
chance of directly gaining useful intellectual property around 
any hits that are obtained in screening; development of such 
hits would have to overcome these challenges. However, a 
cyclopropylphenyl scaffold would overcome some of these 
disadvantages, being less lipophilic (cLogP ca. 0.5 log units 
lower than biphenyl), and having greater potential for 
novelty in development. Small molecule modeling [31] has 
shown that a phenyl attached to a substituted cyclopropyl 
group, which itself contains some pi character, can mimic  
a biphenyl moiety with the side chains overlaying well   
(Fig. 7). Such a compound could therefore be envisioned to 
mimic one face of an alpha helix (Generally, only one face 
of a helix is involved in the interaction with another protein, 
the opposite face usually being buried in the interior of the 
protein itself). Whilst the primary aim is to generate 
compounds with sufficient activity to interfere with a PPI 
selectivity is also considered. By ensuring an adequate 
coverage of chemical space in the selection of the 
substituents we anticipate that screening the library in its 
entirety should lead to differing selectivity patterns 
emerging. 
  Based on this series of simple observations it has been 
possible to devise a number of libraries that can mimic the 
side-chain vectors presented by alpha helices. 
CASE STUDIES 
Performance of BioFocus Kinase-Focused Libraries in 
Kinase Screens 
  Three types of kinase-focused libraries have been 
developed by BioFocus, namely the SoftFocus (SFK), 
FieldFocus (FFK) and ThemePair Fragment (TPF) libraries. 
These latter libraries were designed based on the scaffolds 
and close analogues of fully elaborated kinase-focused 
libraries and their average molecular weight is consequently 
in the 240-dalton range. The Galapagos group has screened 
many of these libraries against various kinases in the context 
of its internal research programs. The results of these screens 
were analyzed in terms of hit rates against 17 kinases that 
represent the major kinase families (AGC: 2 examples, TKL: 
2, TK: 4, STE: 4, CK1: 1, CGMC: 3, and CAMK: 1). A hit is 
defined as a compound exhibiting more than 50% inhibition 
at 10 M in a single-point, primary screening experiment 
and all libraries for which at least a total of 600 single-point 
determinations were made are included in the analysis. 
  The overall hit rates for all kinase-focused libraries 
against all 17 kinases tested is shown in Fig. (8). 89% of the 
kinase-focused libraries have higher hit rates than the diverse 
collection (“DIV”, 5,718 compounds), up to a hit rate of 
31% for SFK52. Considering the size of the ThemePair 
Fragment molecules, their hit rates are surprisingly high 
(between 2.2 and 9.9%), indicating that kinase-focused 
fragments can be highly ligand efficient. 
  Overall hit rates are important, but consideration must 
also be given to the selectivity of each library against the 17 
kinases. Fig. (9) shows a heat map for the SFK libraries. It is 
immediately clear that the pattern is far from homogeneous: 
some kinases (e.g. Kin10) are hit by many libraries, some are 
hit by few, but all kinases are hit by at least one library. 528   Combinatorial Chemistry & High Throughput Screening, 2011, Vol. 14, No. 6  Harris et al. 
  The individual libraries are also complementary: SFK52 
hits many kinases (average hit rate 31.3%), so it is important 
to have SFK52 in a kinase screening collection, despite 
possible selectivity issues. Kin04 is hardly hit by SFK52 
(1.2%), but it is hit strongly by SFK36 (22.6%), which, in 
terms of overall hit rate (6.8%), only takes 12th place. Had 
SFK36 not been included in the screening deck of Kin04, the 
most appealing series would have been missed. It is clear 
that only screening those libraries with high overall hit rates 
(if it is at all possible to determine that a priori) is not 
sufficient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Overall hit rates for each library against all 17 kinases. For comparison, the hit rate (1.7%) of a diverse, non-specifically kinase-
focused collection (“DIV”, grey bar) is provided as well. SFKs are represented by orange, FFKs by green and TPFs by cyan bars (For 
interpretation of the references to color in this figure legend, the reader is referred to the web version of this paper). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (9). Hit rates of each library against each of the 17 kinases. Cells with hit rates > 50% are colored red. Cells with hit rates < 50% have 
colors ranging from white (0% hit rate) to red (50% hit rate). If fewer than 40 compounds in a library were tested against a kinase, the 
corresponding cell is grey (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this 
paper). Design and Application of Target-Focused Compound Libraries  Combinatorial Chemistry & High Throughput Screening, 2011, Vol. 14, No. 6    529 
  Of course, both the target kinase and the library may be 
promiscuous. Indeed, Kin10 is hit by many libraries, which 
may be of concern if one wants to pursue series having 
intrinsic selectivity versus Kin10. For Kin01, Kin03, Kin07, 
Kin09 and Kin17, SFK10 would serve that purpose as it does 
not hit Kin10. So, although SFK10 hits only 5/17 kinases 
with a hit rate > 3%, it is important to have it in the 
screening collection. The ideal composition of a set of 
kinase-focused libraries is actually a mixture of promiscuous 
and selective libraries. 
  To assess the hit rate distribution for a specific library, 
SFK49, a library with a high hit rate (16.5%), is taken as an 
example. It is based on the aminoimidazothiadiazole scaffold 
shown in Fig. (10). 
N
N N
NS
A
B
 
Fig. (10). Scaffold of library SFK49 with substitution points A and 
B indicated. 
 Fig.  (11) shows a heatmap, representing the hit rate of 
each of the 501 compounds of SFK49. There is a clear 
spread of actives over the heatmap: 138 compounds (28%) 
hit no kinase and 88 compounds (18%) hit only one. At the 
other end of the selectivity range, 4 compounds hit 75% of 
the kinases and 1 compound hits 80%. Clearly, this library 
contains compounds ranging in profile between almost 
completely indiscriminate and exquisitely selective. With 
regard to the comparative performance of the side chains of 
the SFK49 library, compounds with R
1=A03 and compounds 
with R
2=B07 have the highest hit rates. However, the 
compound with R
1=A03 and R
2=B07 is not the best compound 
in the library, indicating that R
1 and R
2 substitutions are not 
independent variables and that the combinatorial nature of the 
library provides important information. 
  In conclusion, it is clear that tailor-made, focused kinase 
libraries are a very valuable resource for the development of 
novel and selective kinase inhibitors and represent a more 
efficient entry to novel kinase leads than diverse screening sets. 
Performance of BioFocus Ion Channel-Focused Libraries 
in Ion Channel Screens 
  Researchers at Galapagos and BioFocus have screened a 
range of ion channel-focused libraries against a limited set of 
ion channel targets, the results of which are analyzed below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (11). Hit rates of all compounds of library SFK49 against the 17 kinases. Substitutions in position A are on the Y-axis, in position B on 
the X-axis. Tested (total number of compounds tested), Active (total number of compounds that are active, i.e., that hit at least one kinase), 
Average (average hit rate) and Sum (sum of all hit rates) refer to all compounds in a row or column. Colors range from white (0% hit rate) to 
red (80% hit rate). If a compound was not synthesized or tested, the corresponding cell is grey (for interpretation of the references to color in 
this figure legend, the reader is referred to the web version of this paper. 
B01 B02 B03 B04 B05 B06 B07 B08 B09 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 Tested Active Average Sum
A 0 12 0 4 0 2 7 0 1 3 1 3 4 4 70 4 4 7000 4 4 00 1 3 5 0 3 3 2 2 7 2 2 1 5 1 7 3 8 5
A02 27 7 13 0 0 0 25 0 0 20 14 0 0 0 13 0 25 50 11 21 0 11 22 12 11 237
A03 20 47 7 40 20 44 44 13 40 20 29 53 13 7 33 53 63 38 40 27 14 21 21 32 665
A 0 4 2 01 31 3 7 1 3 7 3 8 0 2 22 1 7 7 4 42 21 33 82 24 42 1 1 44 3 2 1 2 0 2 1 4 3 1
A05 20 13 27 33 0 7 50 7 0 33 22 0 0 0 50 7 22 38 25 0 20 14 18 354
A06 20 20 27 20 0 50 0 7 27 14 0 0 0 33 13 0 25 29 22 0 20 13 15 307
A07 20 27 20 27 33 44 38 7 20 0 20 53 11 40 0 38 38 13 50 19 17 26 498
A08 20 13 27 7 13 50 13 20 27 0 0 7 36 27 13 50 38 50 0 19 16 22 410
A09 20 13 13 20 0 0 38 7 0 20 29 0 0 38 0 25 38 25 13 19 13 16 298
A10 7 0 13 7 0 0 0 0 20 0 7 0 33 0 0 38 25 14 0 19 9 9 163
A11 20 20 0 0 0 38 0 0 22 29 0 0 0 22 0 0 38 0 0 19 7 10 188
A 1 2 0000 000070 1 3 0 0000 1 3 07 1 9 4 2 3 9
A13 13 13 13 7 7 25 13 7 0 20 0 21 7 44 25 25 11 0 18 15 14 252
A14 13 7 13 0 11 25 7 7 7 0 0 25 0 25 38 25 25 0 18 13 13 227
A15 13 20 20 20 0 0 38 0 7 20 14 0 0 25 13 44 14 0 18 12 14 249
A 1 6 70700 1 3 0 2 0 1 1 0 0 1 3 0 1 3 1 3 7 1 4 1 7 1 0 7 1 1 6
A17 20 20 20 7 50 7 33 21 0 0 38 7 25 22 0 15 12 18 269
A18 13 20 20 7 75 7 33 0 0 11 7 0 38 11 0 15 11 16 241
A19 20 20 20 7 20 13 13 20 14 27 13 0 13 13 14 13 15 211
A20 20 7 0 11 22 20 13 13 7 13 7 7 11 7 14 13 11 158
A21 11 0 22 11 0 33 0 13 22 11 0 25 0 21 14 9 12 171
A22 67 53 60 40 27 33 44 47 40 13 67 53 56 13 13 46 600
A23 33 27 33 22 33 27 38 7 29 20 0 7 38 13 12 24 312
A24 20 20 7 75 0 33 63 0 50 50 36 75 12 10 36 429
A25 7 7 7 7 0 0 0 0 27 0 20 11 6 7 73
A26 22 30 20 0 33 27 33 33 33 38 10 9 27 270
A27 7 0 0 11 0 7 7 0 0 0 10 4 3 31
A28 0 0 0 7 20 0 0 0 0 0 10 2 3 27
A29 44 56 22 56 22 11 33 33 8 8 35 278
A30 56 50 40 22 40 73 75 7 7 51 356
A31 40 33 33 27 53 27 63 7 7 39 276
A32 53 80 64 67 4 4 66 264
A33 27 40 38 3 3 35 104
A34 7 7 7 33 7 2 0
A35 30 44 0 3 2 25 74
A36 11 13 2 2 12 24
A37 13 1 1 13 13
A38 20 1 1 20 20
Tested 29 29 27 25 25 25 24 24 24 23 22 22 22 21 20 20 20 19 18 17 17 17 4 4 3
Active 27 23 25 20 16 14 22 15 14 23 18 10 9 6 19 15 8 14 17 17 15 7423
Average1 82 01 92 31 11 33 6 9 92 31 61 11 1 23 02 3 82 53 23 12 3 51 7 75 6
Sum 516 590 518 576 272 318 853 207 222 540 357 238 247 51 595 462 160 469 574 525 395 93 69 29 168530   Combinatorial Chemistry & High Throughput Screening, 2011, Vol. 14, No. 6  Harris et al. 
  Galapagos screened several BioFocus ion channel-
focused libraries (SFI01-SFI13 and FFI01-FFI03) and a 
diverse vendor collection (“DIV”, 1,058 compounds) against 
two internal targets: a potassium VGIC (target A) and a 
calcium non-VGIC (target B). These assays were run in flux 
mode (Rb
+ efflux for A, Ca
2+ influx for B) at 10μM 
compound concentration, a hit being defined by  50% 
inhibition of ion flux. The primary screening data are 
summarized in Fig. (12). The compounds screened against 
both targets A and B are a subset (1,743 compounds) of 
those screened against targets A (1,858) and B (7,867). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (12). Hit rate of each ion channel-focused library against target 
A (pane a), target B (pane b) and targets A and B (pane c). For 
comparison, the hit rate of a diverse, vendor collection (“DIV”) is 
provided as well. 
  Of the libraries tested against both targets A and B, 
SFI06, SFI07, FFI02 and FFI03 in particular show much 
higher hit rates than the diverse set. Overall hit rates for 
target B are higher than for target A. For target B only 5 out 
of the 16 focused libraries exhibited hit rates lower than the 
diverse set. For target A, 4 out of the 7 focused libraries 
tested showed better hit rates than the vendor set, with SFI05  
showing the highest hit rate. Of the compound sets tested 
against both targets (Fig. 12c), SFI04 was completely 
selective for target B, with SFI02 and SFI06 showing weaker 
B selectivity. Interestingly, although the library design was 
not aimed at selectivity for these two channels, the large 
majority of the observed hit compounds were selective for 
one or the other channel. Conversely, at the library level, all 
libraries, except SFI04 and to a lesser extent SFI06, showed 
promiscuity for these two targets. These selectivity data 
mirror the more detailed observations noted above with the 
kinase-focused libraries. 
  BioFocus screened a small set of SFI01 compounds 
against two potassium VGICs (KCNQ2/3 and IK), one 
calcium VGIC (Cav) and one sodium VGIC (Nav1.5), using 
ion flux as a measure of activity in non voltage-clamped 
cells [32]. Two micromolar hits exhibited clear signs of 
selectivity for the calcium channel (compound A for Cav) 
and for one of the potassium channels (compound B for 
KCNQ2/3), respectively (Table 3), demonstrating that 
exquisite selectivity can be obtained with a single library. 
Table 3.  IC50s (in μM) of Two SFI01 Compounds Against 4 
VGICs 
 
 KCNQ2/3  IK  Cav  Nav1.5   
Compound A  >100  >100  1.74  23.64 
Compound B  1.6  >100  11.66  >100 
 
  In summary, the use of specifically designed, focused ion 
channel libraries offers a useful alternative to the screening 
of diverse compound sets and appears to be an excellent 
means to the discovery of selective compounds across a 
range of channel types. As all the compounds discussed here 
act as inhibitors of ion currents, it remains to be seen if such 
libraries also offer an entry point for the development of 
channel activators. 
SUMMARY AND CONCLUSION 
  The customized design of libraries focused on the major 
gene families has been explored in detail, some findings 
from which are highlighted in this paper. Although the 
recycling of existing knowledge of ligands can be criticized 
on the grounds of intellectual property novelty, when such 
information is combined with new structure-based design 
paradigms and/or new insights into the way ligands interact 
with their targets, such as described herein, the observed 
efficiency of focused library screening becomes more 
understandable. Although drug property space is far from 
random, the use of diverse libraries will always have a place 
in discovery for its ability to produce the unexpected, but in 
terms of efficiency and, perhaps, scientific understanding, 
well-designed, focused libraries will continue to make a 
growing impact on drug discovery, as the case studies in this 
paper illustrate. For the future, as the understanding of 
structural relationships between apparently unrelated 
proteins increases, we expect focused libraries to be key 
tools for drug discovery across, as well as within, currently 
perceived protein target families. 
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